The finding of an increased GABA level in AD merits further study, which may benefit from tools and animal models developed from genetic epilepsy with defective GABA transporters, such as those caused by SLC6A1 mutations [51,52]. The gene discussed is SLC6A1; the disease is Alzheimer disease.